R&D in the Pharmaceutical Industry: A World of Small Innovations

References

• Bhattacharya J., Vogt W. B. A simple model of pharmaceutical price dynamics. J. Law Econom. (2003) 46(2):599–626Crossref, Google Scholar
• Bulow J. I., Jaffe A. B., Stern S., Lerner J. The gaming of pharmaceutical patents. Innovation Policy and the Economy (2004) 4(NBER Books, MIT Press, Cambridge, MA) 145–187Google Scholar
• Caves R. E., Whinston M. D., Hurwitz M. A. Patent expiration, entry and competition in the U.S. pharmaceutical industry. Brookings Papers Econom. Activity, Microeconomics (1991) 1–48Crossref, Google Scholar
• Consumer Reports Consumer Reports Best Buy Drugs. (2005) . http://www.crbestbuydrugs.org/PDFs/2pager_ADHD.pdfGoogle Scholar
• Coscelli A. The importance of doctors' and patients' preferences in the prescription decision. J. Indust. Econom. (2000) 48(3):349–369Crossref, Google Scholar
• Danzon P. M., Chao L. W. Does regulation drive out competition in the pharmaceutical markets? J. Law Econom. (2000) 43:311–357Crossref, Google Scholar
• Danzon P. M., Keuffel E., Rose N. L. Regulation of the pharmaceutical-biotechnology industry. Economic Regulation and Its Reform: What Have We Learned? (2007) (Chicago University Press, Chicago) . ForthcomingGoogle Scholar
• DiMassi J. A., Paquette C. The economics of follow-on drug research and development. Pharmacoeconomics (2004) 2(Suppl.):1–14Crossref, Google Scholar
• Duggan M., Scott-Morton F. M. The distortionary effects of government procurement: Evidence from medicaid prescription drug purchasing. Quart. J. Econom. (2006) 121(1):1–30Google Scholar
• Economist, The An overdose of bad news. Special report: The drug industry. The Economist (2005) March 17Google Scholar
• Edlin A. S., Shannon C. Strict monotonicity in comparative statics. J. Econom. Theory (1998) 81(1):201–219Crossref, Google Scholar
• Frank R. G., Salkever D. S. Pricing, patent loss and the market for pharmaceuticals. Southern Econom. J. (1992) 59:165–179Crossref, Google Scholar
• Ganuza J.-J., Llobet G., Domínguez B. R&D in the pharmaceutical sector: A world of small innovations. (2006) . CEMFI Working Paper 0601, CEMFI, Madrid, SpainGoogle Scholar
• Hassett K. A. Price controls and the evolution of pharmaceutical markets. (2004) . Report, American Enterprise Institute, Washington, D.C.Google Scholar
• Hellerstein J. K. The importance of the physician in the generic versus trade-name prescription decision. RAND J. Econom. (1998) 29(1):108–136Crossref, Google Scholar
• Henry J. Kaiser Family Foundation, The Impact of direct-to-consumer advertising on prescription drug spending. (2003) . Report, The Henry J. Kaiser Family Foundation, Menlo Park, CA, http://www.kff.org/rxdrugs/6084-index.cfmGoogle Scholar
• Henry J. Kaiser Family Foundation, The Prescription drug trends fact sheet—May 2007. (2007) . Report, The Henry J. Kaiser Family Foundation, Menlo Park, CA, http://www.kff.org/rxdrugs/3057.cfmGoogle Scholar
• Hollis A. Me-too drugs: Is there a problem? (2004) . Mimeo, University of Calgary, Alberta, CanadaGoogle Scholar
• Hollis A. An efficient reward system for pharmaceutical innovation. (2005) . Mimeo, University of Calgary, Alberta, CanadaGoogle Scholar
• Hong S. H., Shepherd M. D., Scoones D., Wan T. T. H. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration. J. Managed Care Pharmacy (2005) 11(9):746–754Crossref, Google Scholar
• King C. Marketing, product differentiation and competition in the market for antiulcer drugs. (2002) . HBS Working Paper 01-014, Harvard Business School, BostonCrossref, Google Scholar
• Kolata G. Co-payments soar for drugs with high prices. New York Times (2008) April 14). http://www.nytimes.com/2008/04/14/us/14drug.htmlGoogle Scholar
• Lexchin J. Intellectual property rights and the Canadian pharmaceutical marketplace: Where do we go from here? (2003) . Report, Canadian Centre for Policy Alternatives, Ontario, Canada, http://www.policyalternatives.ca/documents/National_Office_Pubs/ipr.pdfGoogle Scholar
• Love J. Evidence regarding research and development investments in innovative and non-innovative medicines. (2003) . Report, Consumer Project on Technology, Washington, D.C., http://www.cptech.org/ip/health/rnd/evidenceregardingrnd.pdfGoogle Scholar
• Manchanda P., Chintagunta P. K. Responsiveness of physician prescription behavior to salesforce effort: An individual level analysis. Marketing Lett. (2004) 15(2):129–145Crossref, Google Scholar
• Milgrom P. R., Shannon C. Monotone comparative statics. Econometrica (1994) 62(1):157–180Crossref, Google Scholar
• Nordhaus W. D.Invention, Growth, and Welfare; A Theoretical Treatment of Technological Change (1969) (MIT Press, Cambridge, MA) Google Scholar
• Ridley D. Payments, promotion and the purple pill. (2004) . Working paper, Fuqua School of Business, Duke University, Durham, NCGoogle Scholar
• Salop S. C., Stiglitz J. E. Bargains and ripoffs: A model of monopolistically competitive price dispersion. Rev. Econom. Stud. (1977) 44(3):493–510Crossref, Google Scholar
• United States Government Accountability Office New drug development: Science, business, regulatory and intellectual property issues cited as hampening drug development efforts. (2006) . Report, U.S. Government Accountability Office, Washington, D.C., http://www.gao.gov/new.items/d0749.pdfGoogle Scholar